Recently, the SUMO-activating enzyme SAE1 was found to promote human glioma progression by enhancing Akt SUMOylation-mediated signaling and propose targeting Akt SUMOylation as a promising therapeutic strategy [73]. This evidence concerns the gene SAE1 and central nervous system cancer.